pCDCAR1 CD19 h(8ζ), T(CAR-T-2-L332-8Z)
The vector of anti-CD19 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD19. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to a CD8 hinge-transmembrane domain and CD3-zeta signaling domains. And the vector product was designed for the treatment of chronic lymphoid leukemia.
Targeting Cell Type
Chronic lymphocytic leukemia (CLL)
Discription of Signaling Cassetes
CD8 CD8 (cluster of differentiation 8) is a transmembrane glycoprotein that serves as a co-receptor for the T cell receptor(TCR). Like the TCR, CD8 binds to a major histocompatibility complex (MHC) molecule, but is specific for the class I MHC protein. This affinity between CD8 and MHC molecule keeps the chimeric T cell receptor and the target cell bound closely together during antigen-specific activation.
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta,which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T cell surface antigen Leu-12; B-lymphocyte surface antigen B4; Chronic Lymphocytic Leukemia; CLL; scFv; CD28; Leukemia; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; FMC63
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Anti-CD19 (SJ25C1) h(OX-40-CD3ζ) CAR, pCDCAR1
||Anti-CD19 scFv h(CD28-FcεRIγ) CARNK, pCDCAR1
||Anti-CD19 scFv h(CD28-FcεRIγ) CART, pCDCAR1
||Anti-CD19 (Denintuzumab) scFv h(CD3ζ) CAR, pCDCAR1
||Anti-CD19 h(VNAR-41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (47G4) h(CD28-CD27-FcεRIγ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-CD28-CD27-FcεRIγ, 47G4) Viral Particle
||Anti-CD19 (S1) h(CD28-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (SJ25C1) h(DAP10-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (SJ25C1) h(41BB-CD3ζ) CAR, pCDCAR1